Pfizer has voluntarily pulled its pulmonary arterial hypertension (PAH) drug Thelin (sitaxentan) from the markets in which it is approved - the EU, Canada and Australia - and is discontinuing ongoing clinical studies after three drug-related deaths occurred, due to liver toxicity.
While liver toxicity is a known complication of the class of drugs to which Thelin belongs, a new potentially life-threatening idiosyncratic risk
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?